Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$1.1 billion.

  • Spyre Therapeutics' Retained Earnings fell 2006.95% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 2006.95%. This contributed to the annual value of -$972.4 million for FY2024, which is 2721.27% down from last year.
  • Per Spyre Therapeutics' latest filing, its Retained Earnings stood at -$1.1 billion for Q3 2025, which was down 2006.95% from -$1.1 billion recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Retained Earnings high stood at -$294.2 million for Q1 2021, and its period low was -$1.1 billion during Q2 2025.
  • For the 5-year period, Spyre Therapeutics' Retained Earnings averaged around -$640.9 million, with its median value being -$661.1 million (2023).
  • As far as peak fluctuations go, Spyre Therapeutics' Retained Earnings plummeted by 8203.07% in 2024, and later crashed by 2006.95% in 2025.
  • Spyre Therapeutics' Retained Earnings (Quarter) stood at -$341.8 million in 2021, then dropped by 24.52% to -$425.6 million in 2022, then crashed by 79.6% to -$764.4 million in 2023, then dropped by 27.21% to -$972.4 million in 2024, then fell by 13.12% to -$1.1 billion in 2025.
  • Its Retained Earnings stands at -$1.1 billion for Q3 2025, versus -$1.1 billion for Q2 2025 and -$1.0 billion for Q1 2025.